Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function - PubMed (original) (raw)
. 2016 Aug 16;7(33):53820-53836.
doi: 10.18632/oncotarget.10781.
Shuhei Komatsu 1, Daisuke Ichikawa 1, Mahito Miyamae 1, Tsutomu Kawaguchi 1, Shoji Hirajima 1, Takuma Ohashi 1, Taisuke Imamura 1, Jun Kiuchi 1, Tomohiro Arita 1, Hirotaka Konishi 1, Atsushi Shiozaki 1, Ryo Moriumura 1, Hisashi Ikoma 1, Kazuma Okamoto 1, Hiroki Taniguchi 2, Yoshito Itoh 3, Eigo Otsuji 1
Affiliations
- PMID: 27462777
- PMCID: PMC5288224
- DOI: 10.18632/oncotarget.10781
Circulating microRNA profiles in plasma: identification of miR-224 as a novel diagnostic biomarker in hepatocellular carcinoma independent of hepatic function
Wataru Okajima et al. Oncotarget. 2016.
Abstract
Aims: This study was designed to identify novel microRNAs (miRNAs) in plasma for detecting and monitoring hepatocellular carcinoma (HCC), independent of hepatic function and background liver diseases with different etiologies.
Results: (1) Four oncogenic miRNAs (miR-151, 155, 191 and 224) with high expression in HCC tissues were selected as candidates. (2) Quantitative RT-PCR using plasma samples from 107 HCC patients and 75 healthy volunteers revealed a significantly higher level of plasma miR-224 in HCC patients than in healthy volunteers according to a small-scale analysis (P < 0.0001), two independent large-scale cohort analysis (P < 0.0001, AUC 0.908). (3) miR-224 expression was significantly higher in HCC tissues and HCC cell lines than in normal hepatic tissues and fibroblasts, respectively. (P = 0.0011, 0.0150) (4) Plasma miR-224 reflected tumor dynamics; preoperative plasma levels of miR-224 were significantly reduced in postoperative samples (P = 0.0058), and plasma miR-224 levels were significantly correlated with paired miR-224 levels in HCC tissues (P = 0.0005). (5) Furthermore, plasma miR-224 levels significantly discriminated HCC patients from patients with chronic liver disease (P = 0.0008). A high plasma miR-224 level was significantly correlated with larger tumor size (P = 0.0005) and recurrences (P = 0.0027). The plasma miR-224 level could accurately detect small tumors less than 18 mm preoperatively.
Methods: We performed a systematic review of the NCBI database and selected candidate miRNAs reported as highly expressed in HCC tissue.
Conclusions: Plasma miR-224 may be a sensitive biomarker for screening HCC and monitoring tumor dynamics.
Keywords: circulating microRNA; liquid biopsy; liver cirrhosis; plasma; tumor marker.
Conflict of interest statement
We have no financial relationships to disclose.
Figures
Figure 1
A. Selection of the candidate microRNAs from the NCBI database. B. Study design to identify novel plasma miRNA biomarkers for HCC. Using a systematic review of the NCBI database, we selected four candidate miRNAs for cancer detection and monitoring. Candidate miRNAs, previously reported to have an oncogenic role in HCC and previously confirmed in tissues or cell lines but not in body fluids, were selected. Among these, the expression level of plasma miR-224 showed the most significant difference (P < 0.0001). Thus, further analyses of plasma miR-224 were conducted.
Figure 2. Small-scale analyses comparing the plasma levels of four candidate miRNAs between HCC patients and healthy volunteers
Plasma levels of the four candidate miRNAs in 20 HCC patients and 20 healthy volunteers were analyzed using qRT-PCR. The expression level of each miRNA was normalized to that of cel-miR-39 as described in the Materials and Methods. All candidate miRNAs showed significantly higher expression levels in HCC patients than in healthy volunteers. Among these, the expression level of plasma miR-224 showed the most significant difference (P < 0.0001).
Figure 3
A, B. Confirmation of the expression level of miR-224 in HCC tissues and HCC cell lines. miR-224 expression was significantly higher in HCC tissues (P = 0.0011) and HCC cell lines (P = 0.0150) than in normal tissues and fibroblasts, respectively. C. Large-scale analysis of the plasma level of miR-224 in HCC patients using a validation cohort. The expression level of plasma miR-224 was significantly higher in HCC patients than in healthy volunteers (P < 0.0001), and this finding was validated in large-scale analysis (AUC was 0.908). For the large-scale analysis, total RNA extracted from plasma samples obtained from 87 HCC patients and 55 age-matched healthy volunteers were used to analyze the expression level of miR-224 using qRT-PCR. D. The correlation between the plasma and the tissue levels of miR-224 were confirmed in HCC patients using paired samples (P = 0.0005). E. Evaluation of whether the plasma miR-224 levels reflect tumor dynamics. The expression level of miR-224 was significantly reduced in postoperative plasma samples (P = 0.0058).
Figure 4. Evaluation of whether the plasma miR-224 level could satisfactory distinguish early stage HCC patients form healthy volunteers
The expression level of plasma miR-224 was significantly higher in stage I HCC patients than in healthy volunteers (P < 0.0001). The AUC values in the LCSGJ and TNM (AJCC/UICC) staging systems for the plasma miR-224 analysis were 0.888 and 0.899, respectively.
Figure 5. Evaluation of tumor detection based on the plasma miR-224 level, independent of chronic hepatic disease and hepatic function
A. There were no significant differences in the plasma miR-224 levels among patients with HBV, HCV and other disease in the large-scale analysis (P = 0.3087). B, C. The plasma miR-224 levels were significantly higher in the plasma of HCC patients compared with non-HCC outpatients among patients with mild (P < 0.0001) or severe liver dysfunction (P = 0.0008).
Figure 6. Correlation between the plasma level of miR-224 and conventional serum tumor markers and indicators of hepatic functions in HCC patients
No significant correlation was observed between the plasma miR-224 levels and other clinical indicators, such as the tumor makers PIVKA-II (DCP) and AFP, the ICG retention rate (ICG 15R), total bilirubin (T-Bil), albumin (Alb), prothrombin time (PT (%)), aspartate transaminase (AST) and alanine transaminase (ALT).
Figure 7. Post-treatment plasma miR-224 level as a sensitive indicator of residual tumor during HCC treatment
Current tumor markers and imaging modalities, such as Lipiodol®-CT and dynamic MRI, have limitations in the detection of residual tumor after local therapy for HCC. (A) The plasma miR-224 level was significantly higher in patients with residual tumors than in patients with no remaining cancer cells (P = 0.0318) (B) In these patients, conventional tumor markers and dynamic MRI could not discriminate residual HCC.
Similar articles
- The predictive powers of plasma trefoil factor 3 or its related micro RNAs for patients with hepatocellular carcinoma.
Zhang C, Xia R, Zhang B, Wang H. Zhang C, et al. BMC Cancer. 2018 Nov 13;18(1):1110. doi: 10.1186/s12885-018-5017-y. BMC Cancer. 2018. PMID: 30424721 Free PMC article. - Plasma miR-15b-5p, miR-338-5p, and miR-764 as Biomarkers for Hepatocellular Carcinoma.
Chen Y, Chen J, Liu Y, Li S, Huang P. Chen Y, et al. Med Sci Monit. 2015 Jun 29;21:1864-71. doi: 10.12659/MSM.893082. Med Sci Monit. 2015. PMID: 26119771 Free PMC article. - Hepatic miR-126 is a potential plasma biomarker for detection of hepatitis B virus infected hepatocellular carcinoma.
Ghosh A, Ghosh A, Datta S, Dasgupta D, Das S, Ray S, Gupta S, Datta S, Chowdhury A, Chatterjee R, Mohapatra SK, Banerjee S. Ghosh A, et al. Int J Cancer. 2016 Jun 1;138(11):2732-44. doi: 10.1002/ijc.29999. Epub 2016 Feb 8. Int J Cancer. 2016. PMID: 26756996 - Identification of circulating MicroRNAs as novel potential biomarkers for hepatocellular carcinoma detection: a systematic review and meta-analysis.
Li G, Shen Q, Li C, Li D, Chen J, He M. Li G, et al. Clin Transl Oncol. 2015 Sep;17(9):684-93. doi: 10.1007/s12094-015-1294-y. Epub 2015 May 9. Clin Transl Oncol. 2015. PMID: 25956842 Review. - Circulating microRNAs in Hepatocellular Carcinoma: Potential Diagnostic and Prognostic Biomarkers.
Mirzaei HR, Sahebkar A, Mohammadi M, Yari R, Salehi H, Jafari MH, Namdar A, Khabazian E, Jaafari MR, Mirzaei H. Mirzaei HR, et al. Curr Pharm Des. 2016;22(34):5257-5269. doi: 10.2174/1381612822666160303110838. Curr Pharm Des. 2016. PMID: 26935703 Review.
Cited by
- Diagnostic, prognostic, and therapeutic potential of exosomal microRNAs in renal cancer.
Yu X, Du Z, Zhu P, Liao B. Yu X, et al. Pharmacol Rep. 2024 Apr;76(2):273-286. doi: 10.1007/s43440-024-00568-7. Epub 2024 Feb 22. Pharmacol Rep. 2024. PMID: 38388810 Review. - Predictive Role of Pretreatment Circulating miR-221 in Patients with Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization.
Pinjaroen N, Chailapakul P, Sriphoosanaphan S, Chuaypen N, Tangkijvanich P. Pinjaroen N, et al. Diagnostics (Basel). 2023 Aug 29;13(17):2794. doi: 10.3390/diagnostics13172794. Diagnostics (Basel). 2023. PMID: 37685331 Free PMC article. - BL-MOL-AR Project, Preliminary Results about Liquid Biopsy: Molecular Approach Experience and Research Activity in Oncological Settings.
Pancrazzi A, Bloise F, Moncada A, Perticucci R, Vecchietti S, Pompili F, Ricciarini F, Lenzi S, Gatteschi C, Giusti S, Rosito MP, Del Buono S, Belardi P, Bruni A, Borri F, Campione A, Laurini L, Occhini R, Presenti L, Viticchi V, Rossi M, Bardi S, D'Urso A, Dei S, Venezia D, Scala R, Bengala C, Decarli NL, Carnevali A, Milandri C, Ognibene A. Pancrazzi A, et al. Glob Med Genet. 2023 Jul 14;10(3):172-187. doi: 10.1055/s-0043-1771193. eCollection 2023 Sep. Glob Med Genet. 2023. PMID: 37457625 Free PMC article. - Liquid Biopsies, Novel Approaches and Future Directions.
Armakolas A, Kotsari M, Koskinas J. Armakolas A, et al. Cancers (Basel). 2023 Mar 3;15(5):1579. doi: 10.3390/cancers15051579. Cancers (Basel). 2023. PMID: 36900369 Free PMC article. Review. - Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma.
Zhou Y, Liu F, Ma C, Cheng Q. Zhou Y, et al. J Clin Lab Anal. 2022 Oct;36(10):e24673. doi: 10.1002/jcla.24673. Epub 2022 Aug 29. J Clin Lab Anal. 2022. PMID: 36036748 Free PMC article. Review.
References
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer. 2015;136:E359–386. - PubMed
- Parkin DM. The global health burden of infection-associated cancers in the year 2002. International journal of cancer. 2006;118:3030–3044. - PubMed
- Mayans MV, Calvet X, Bruix J, Bruguera M, Costa J, Esteve J, Bosch FX, Bru C, Rodes J. Risk factors for hepatocellular carcinoma in Catalonia, Spain. International journal of cancer. 1990;46:378–381. - PubMed
- Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, Decarli A, Trevisi P, Ribero ML, Martelli C, Porru S, Nardi G. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. American journal of epidemiology. 2002;155:323–331. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical